Virtual work is easier because of the cost effectiveness of teleconferencing and video conferencing.
For clinical/CD4, lower mortality worsens the ICER because the ICER approaches the cost effectiveness of keeping individuals alive on ART (that is, cost and a year's DALYs v death and no cost).
This is because the cost-effectiveness of a diagnostic strategy depends in part on the consequences for subsequent treatment.
This study is innovative because the (cost- effectiveness of a stepped-cost- effectivenessrevent depressiof and anxiety has never been tested in a visually improgrammepulatoon before.
However, it requires context-specific analysis because the cost-effectiveness of Strategy 3 appears sensitive to the unit cost of X-ray which varies among different countries and localities.
Seventh, we did not focus on the cost of the intervention because the cost-effectiveness of the intervention was beyond the scope of this study, although we saved costs by introducing health educators without professional license.
Of those remaining, 8 publications were excluded because the cost-effectiveness of the strategy was not measured in a maternal or newborn population, though we did include one article that reported the cost per infant death averted.
Because the cost-effectiveness of a PCV program could be affected by potential serotype replacement or herd immunity effects that may not be known until after a large scale introduction, type-specific surveillance and iterative evaluation will be critical.
In general, current trials have omitted the many opportunities to develop these, ultimately depriving patients who may respond of therapy because the cost-effectiveness of treating all-comers is too low.
However, because the cost-effectiveness of a PCV program could be affected by potential serotype replacement or herd immunity effects that may be realized after a large-scale introduction, the importance of iterative evaluation as surveillance data become available cannot be overstated.
This approach remains controversial because of doubts about the cost-effectiveness of screening biopsies in this population, where the rate of progression to malignancy is still relatively low (estimates suggest 1 in 50 200 per year) whilst the diagnosis of HGD from limited biopsies can be extremely difficult [ 5- 8].
